ANGLE plc (GB:AGL) has released an update.
ANGLE plc celebrates a significant milestone with the 100th peer-reviewed publication validating their Parsortix system, which has been instrumental in cancer research across 24 cancer types over the past decade. The latest study from Italy showcases the system’s ability to isolate cancer cells for Whole Genomic Sequencing (WGS), offering a potential cost-effective tool for guiding patient treatment. This advancement underscores the Parsortix system’s role in paving the way for personalized cancer therapies and less invasive diagnostic alternatives.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
